&nbsp;

EsophagealCancerPreventionandEarlyDetectionPathway.pdf

Jan 2023

Document

EsophagealCancerDiagnosisPathway.pdf

Jan 2023

Document

EsophagealCancerFollow-upCarePathway.pdf

Jan 2023

Document

EsophagealCancerTreatmentPathway.pdf

Jan 2023

Regimen

DURV+TREM

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Drugs Used:

tremelimumab,

durvalumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

DOCE+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

DOCEtaxel

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

DARODOCE

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel

Drugs Used:

DOCEtaxel,

darolutamide

Quick Link(s):

Regimen Monograph

Mar 2024

Regimen

DOXO(RT-W)

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Drugs Used:

DOXOrubicin

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

DOCE(RT-W)

Cancer Type:

Head and Neck,

Squamous Cell

Intent: Adjuvant, Curative

Drugs Used:

DOCEtaxel

Quick Link(s):

Regimen Monograph

May 2023

Document

DeclinedReferralForm.docx

Apr 2023

Document